Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.44 |
| ▸ | FAP | Q12884 | 2/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768507 | 1.00 | DPP4 (0.44) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL1189333 | 1.00 | DPP4 (0.44) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL16935735 | 0.98 | DPP4 (0.46) | DPP4DPP7FAPPREPDPP8 | |
| Hydrochloric Acid SCHEMBL9653875 | 0.98 | DPP4 (0.43) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL5891316 | 0.98 | DPP4 (0.46) | DPP4DPP7FAPPREPDPP8 | |
| Hydrochloric Acid SCHEMBL4502967 | 0.98 | DPP4 (0.43) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL8612552 | 0.98 | DPP4 (0.46) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL856280 | 0.98 | DPP4 (0.46) | DPP4DPP7FAPPREPDPP8 | |
| Hydrochloric Acid SCHEMBL3947769 | 0.95 | DPP4 (0.45) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL14656016 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | claimed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | claimed |
| EP-1675578-B1 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2013-05-22 | — | — | EP | claimed |
| EP-1620082-B9 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-08-25 | — | — | EP | claimed |
| EP-1620082-B1 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-04-21 | — | — | EP | claimed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| US-20250144291-A1 | ARTIFICIAL INTELLIGENCE BASED IMPLANTABLE DRUG DELIVERY SYSTEM | Manta Implant LLC (US) | 2025-05-08 | — | — | US | disclosed |
| EP-4522607-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| CN-119317626-A | Pyrrolidone derivatives as inhibitors of NF- κb-induced kinase | 詹森药业有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2024143263-A1 | FLUORESCENCE INTENSITY ENHANCING AGENT, METHOD FOR ENHANCING FLUORESCENCE INTENSITY OF FLUORESCENTLY LABELED TARGET BIOLOGICAL MATERIAL, AND FLUORESCENCE DETECTION KIT | 富士フイルム株式会社 | 2024-07-04 | — | — | WO | disclosed |
| EP-1428533-A2 | Use of thiazolidine- or pyrrolidine-derivatives of aminoacids as antihyperglycemic agents | Probiodrug AG (DE) | 2004-06-16 | — | — | EP | disclosed |
| EP-1398030-A2 | Dipeptidyl peptidase IV effectors | Probiodrug AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1082314-B1 | NEW DIPEPTIDYL PEPTIDASE IV EFFECTORS | PROBIODRUG AG (DE) | 2003-04-23 | — | — | EP | disclosed |
| EP-1304327-A2 | Glutamine-thiazolidide and -pyrrolidide and their use as dipeptidylpeptidase IV inhibitors | Probiodrug AG (DE) | 2003-04-23 | — | — | EP | disclosed |
| EP-1215207-A2 | Salts of isoleucyl-thiazolidine and -pyrrolidine and their use as dipeptidylpeptidase inhibitors | Probiodrug AG (DE) | 2002-06-19 | — | — | EP | disclosed |
| EP-1214936-A2 | Use of thiazolidin- or pyrrolidin-derivatives of aminoacids as antihyperglycemic agents | Probiodrug AG (DE) | 2002-06-19 | — | — | EP | disclosed |
| EP-1082314-A1 | NEW DIPEPTIDYL PEPTIDASE IV EFFECTORS | Probiodrug Gesellschaft für Arzneimittelforschung mbH (DE) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061431-A1 | NEW DIPEPTIDYL PEPTIDASE IV EFFECTORS | Probiodrug Gesellschaft für Arzneimittelforschung mbH (DE) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | DPP4 798/4885DPP7 573/4885FAP 3136/4885 |
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | DPP4 3896/4885DPP7 2511/4885FAP 2269/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | DPP4 911/4885DPP7 491/4885FAP 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.